AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Soluble receptor for advanced glycation end products (sRAGE) acts as a decoy sequestering of RAGE ligands, thus preventing the activation of the ligand-RAGE axis linking human diseases. However, the molecular mechanisms underlying sRAGE remain unclear. In this study, THP-1 monocytes were cultured in normal glucose (NG, 5.5 mmol/L) and high glucose (HG, 15 mmol/L) to investigate the effects of diabetesrelevant glucose concentrations on sRAGE and interleukin-1β (IL-1β) secretion. The modulatory effects of epigallocatechin gallate (EGCG) in response to HG challenge were also evaluated. HG enhanced intracellular reactive oxygen species (ROS) generation and RAGE expression. The secretion of sRAGE, including esRAGE and cRAGE, was reduced under HG conditions, together with the downregulation of a disintegrin and metallopeptidase 10 (ADAM10) and nuclear factor erythroid 2-related factor 2 (Nrf2) nuclear translocation. Mechanistically, the HG effects were counteracted by siRAGE and exacerbated by siNrf2. Chromatin immunoprecipitation results showed that Nrf2 binding to the ADAM10 promoter and HG interfered with this binding. Our data reinforce the notion that RAGE and Nrf2 might be sRAGE-regulating factors. Un der HG conditions, the treatment of EGCG reduced ROS generation and RAGE activation. EGCG-stimulated cRAGE release was likely caused by the upregulation of the Nrf2-ADAM10 pathway. EGCG inhibited HG-mediated NLRP3 inf lammasome activation at least partly by stimulating sRAGE, thereby reducing IL-1β release.
T. Teissier, É. Boulanger, The receptor for advanced glycation endproducts (RAGE) is an important pattern recognition receptor (PRR) for inflammaging, Biogerontology 20 (2019) 279-301. https://doi.org/10.1007/s10522-019-09808-3.
R. Ramasamy, A. Shekhtman, A.M. Schmidt, The RAGE/DIAPH1 signaling axis & implications for the pathogenesis of diabetic complications, Int. J.Mol. Sci. 23 (2022) 4579. https://doi.org/10.3390/ijms23094579.
L. Egaña-Gorroño, R. López-Díez, G. Yepuri, et al., Receptor for advanced glycation end products (RAGE) and mechanisms and therapeutic opportunities in diabetes and cardiovascular disease: insights from human subjects and animal models, Front. Cardiovasc. Med. 10 (2020) 37. https://doi.org/10.3389/fcvm.2020.00037.
R.C. Chellappa, R. Palanisamy, K. Swaminathan, RAGE isoforms,its ligands and their role in pathophysiology of Alzheimer’s disease, Curr. Alzheimer Res. 17 (2020) 1262-1279. https://doi.org/10.2174/1567205018666210218164246.
S. Ahmad, F. Akhter, U. Shahab, eyi t al., Do all roads lead to the Rome?the glycation perspective!, Semin. Cancer Biol. 49 (2018) 9-19. https://doi.org/10.1016/j.semcancer.2017.10.012.
T.A. Eva, N. Barua, M.M. Chowdhury, et al., Perspectives on signaling for biological- and processed food-related advanced glycation end-products and its role in cancer progression, Crit. Rev. Food Sci. Nutr. 62 (2022) 2655-2672. https://doi.org/10.1080/10408398.2020.1856771.
D. Sellegounder, P. Zafari, M. Rajabinejad, et al., Advanced glycation end products (AGEs) and its receptor, RAGE, modulate age-dependent COVID-19 morbidity and mortality. a review and hypothesis, Int.Immunopharmacol. 98 (2021) 107806. https://doi.org/10.1016/j.intimp.2021.107806.
J.D. Erusalimsky, The use of the soluble receptor for advanced glycationend products (sRAGE) as a potential biomarker of disease risk and adverse outcomes, Redox Biol. 42 (2021) 101958. https://doi.org/10.1016/j.redox.2021.101958.
F. Santilli, N. Vazzana, L.G. Bucciarelli, et al., Soluble forms of RAGE in human diseases: clinical and therapeutical implications, Curr. Med. Chem.16 (2009) 940-952. https://doi.org/10.2174/092986709787581888.
L. Zhang, M. Bukulin, E. Kojro, et al., Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases,J Biol. Chem. 283 (2008) 35507-30016. https://doi.org/10.1074/jbc.M806948200.
A. Raucci, S. Cugusi, A. Antonelli, et al., A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10), FASEB J. 22 (2008) 3716-3727. https://doi.org/10.1096/fj.08-109033.
R. Ragavi, P.S. Adole, K.V. Vinod, et al., Altered expression of a disintegrin and metalloproteinase 10 in peripheral blood mononuclear cells in type 2 diabetes mellitus patients with the acute coronary syndrome: a pilot study, Endocrine. 77 (2022) 461-468. https://doi.org/10.1007/s12020-022-03141-5.
A. Antonelli, S.D. Maggio, J. Rejman, et al., The shedding-derived soluble receptor for advanced glycation endproducts sustains inflammation during acute Pseudomonas aeruginosa lung infection, Biochim. Biophys. Acta. Gen.Subj. 1861 (2017) 354-364. http://doi.org/10.1016/j.bbagen.2016.11.040.
J.G. Perez-Silva, Y. Espanol, G. Velasco, et al., The degradome database:expanding roles of mammalian proteases in life and disease, Nucleic Acids Res. 44 (2016) D351-D355. http://doi.org/10.1093/nar/gkv1201.
S. Wetzel, L. Seipold, P. Saftig. The metalloproteinase ADAM10: a useful therapeutic target?, Biochim. Biophys. Acta. Mol. Cell Res. 1864 (2017)2071-2081. http://doi.org/10.1016/j.bbamcr.2017.06.005.
S. Reinhardt, F. Schuck, S. Grosgen, et al., Unfolded protein response signaling by transcription factor XBP-1 regulates ADAM10 and is affected in Alzheimer’s disease, FASEB J. 28 (2014) 978-997. http://doi.org/10.1096/fj.13-234864.
A.C. Lee, J.K. Lam, S.W. Shiu, et al., Serum level of soluble receptor for advanced glycation end products is associated with a disintegrin and metalloproteinase 10 in type 1 diabetes, PLoS One 10 (2015) e0137330.http://doi.org/10.1371/journal.pone.0137330.
M. Brownlee, Biochemistry and molecular cell biology of diabetic complications, Nature 414 (2001) 813-820. https://doi.org/10.1038/414813a.
A.M. Teixeira, C. Sousa, A review on the biological activity of Camellia species, Molecules 26 (2021) 2178. https://doi.org/10.3390/molecules26082178.
C.S. Yang, T. Chen, C.T. Ho, Redox and other biological activities of tea catechins that may affect health: mechanisms and unresolved issues, J. Agric.Food Chem. 70 (2022) 7887-7899. https://doi.org/10.1021/acs.jafc.2c02527.
C.H. Wu, S.M. Huang, G.C. Yen, Silymarin: a novel antioxidant with antiglycation and antiinflammatory properties in vitro and in vivo, Antioxid.Redox. Signal. 14 (2011) 353-366. https://doi.org/10.1089/ars.2010.3134.
A.K. Fenercioglu, T. Saler, E. Genc, et al., The effects of polyphenolcontaining antioxidants on oxidative stress and lipid peroxidation in type 2 diabetes mellitus without complications, J. Endocrinol. Invest. 33 (2010)118-124. https://doi.org/10.1007/BF03346565.
Z. Zhai, Y. Huang, Y. Zhang, et al., Clinical research progress of small molecule compounds targeting Nrf2 for treating inflammation-related diseases, Antioxidants (Basel). 11 (2022) 1564. https://doi.org/10.3390/antiox11081564.
Y. Bai, Q. Mu, X. Bao, et al., Targeting NLRP3 inflammasome in the treatment of diabetes and diabetic complications: role of natural compounds from herbal medicine, Aging Dis. 12 (2021) 1587-1604. https://doi.org/10.14336/AD.2021.0318.
A.N.R. Weber, Z.A. Bittner, S. Shankar, et al., Recent insights into the regulatory networks of NLRP3 inflammasome activation, J. Cell Sci. 133(2020) jcs248344. https://doi.org/10.1242/jcs.248344.
D. Yao, M. Brownlee, Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products(RAGE) and RAGE ligands, Diabetes 59 (2010) 249-255. https://doi.org/10.2337/db09-0801.
S.F. Yan, R. Ramasamy, A.M. Schmidt, The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature, Circ. Res. 106(2010) 842-853. https://doi.org/10.1161/CIRCRESAHA.109.212217.
A. Kosaki, T. Hasegawa, T. Kimura, et al., Increased plasma S100A12 (ENRAGE) levels in patients with type 2 diabetes, J. Clin. Endocrinol. Metab. 89(2004) 5423-5428. https://doi.org/10.1210/jc.2003-032223.
G. Basta, A.M. Sironi, G. Lazzerini, et al., Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein, J. Clin. Endocrinol. Metab. 91 (2006) 4628-4634. https://doi.org/10.1210/jc.2005-2559.
N. Shanmugam, M.A. Reddy, M. Guha, et al., High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells, Diabetes 52 (2003) 1256-1264. https://doi.org/10.2337/diabetes.52.5.1256.
C.H. Wu, C.T. Yeh, P.H. Shih, et al., Dietary phenolic acids attenuate multiple stages of protein glycation and high-glucose-stimulated proinflammatory IL-1β activation by interfering with chromatin remodeling and transcription in monocytes, Mol. Nutr. Food Res. 2 (2010) S127-140.https://doi.org/10.1002/mnfr.200900395.
Z.A. Kohutek, C.G. diPierro, G.T. Redpath, et al., ADAM-10-mediated N-cadherin cleavage is protein kinase C-α dependent and promotes glioblastoma cell migration, J. Neurosci. 29 (2009) 4605-4615. https://doi.org/10.1523/JNEUROSCI.5126-08.2009.
E. Devangelio, F. Santilli., G. Formoso, et al., Soluble RAGE in type 2 diabetes: association with oxidative stress, Free Radic. Biol. Med. 43 (2007)511-518. https://doi.org/10.1016/j.freeradbiomed.2007.03.015.
S.A. Rushworth, D. MacEwan, M.A. O’Connell, Lipopolysaccharideinduced expression of NAD(P)H: quinone oxidoreductase 1 and heme oxygenase-1 protects against excessive inflammatory responses in human monocytes, J. Immunol. 181 (2008) 6730-6737. https://doi.org/10.4049/jimmunol.181.10.6730.
S. Fourquet, R. Guerois, D. Biard, et al., Activation of NRF2 by nitrosative agents and H2O2 involves KEAP1 disulfide formation, J. Biol. Chem. 285(2010) 8463-8471. https://doi.org/10.1074/jbc.M109.051714.
I. Seghrouchni, J. Drai, E. Bannier, et al., Oxidative stress parameters in type Ⅰ, type Ⅱ and insulin-treated type 2 diabetes mellitus; insulin treatment efficiency, Clin. Chim. Acta. 321 (2002) 89-96. https://doi.org/10.1016/s0009-8981(02)00099-2.
K. Zitouni, J. Nourooz-Zadeh, D. Harry, et al., Race-specific differences in antioxidant enzyme activity in patients with type 2 diabetes: a potential association with the risk of developing nephropathy, Diabetes Care 28 (2005)1698-1703. https://doi.org/10.2337/diacare.28.7.1698.
P. Golpour, M. Nourbakhsh, M. Mazaherioun, et al., Improvement of NRF2 gene expression and antioxidant status in patients with type 2 diabetes mellitus after supplementation with omega-3 polyunsaturated fatty acids: a double-blind randomised placebo-controlled clinical trial, Diabetes Res. Clin.Pract. 162 (2020) 108120. https://doi.org/10.1016/j.diabres.2020.108120.
F. He, X.L. Ru, T. Wen, NRF2, a transcription factor for stress response and beyond, Int. J. Mol. Sci. 21 (2020) 4777. http://doi.org/10.3390/ijms21134777.
J.S. Albert-Garay, J.R. Riesgo-Escovar, R. Salceda, High glucose concentrations induce oxidative stress by inhibiting Nrf2 expression in rat Müller retinal cells in vitro, Sci. Rep. 12 (2020) 1261. http://doi.org/10.1038/s41598-022-05284-x.
Q. Zhong, M. Mishra, R.A. Kowluru, Transcription factor Nrf2-mediated antioxidant defense system in the development of diabetic retinopathy, Invest. Ophthalmol. Vis. Sci. 54 (2013) 3941-3948. http://doi.org/10.1167/iovs.13-11598.
S.M. Huang, Y.H. Chang, Y.C. Chao, et al., EGCG-rich green tea extract stimulates sRAGE secretion to inhibit S100A12-RAGE axis through ADAM10-mediated ectodomain shedding of extracellular RAGE in type 2 diabetes, Mol. Nutr. Food Res. 57 (2013) 2264-2268. https://doi.org/10.1002/mnfr.201300275.
T. Clifford, J.P. Acton, S.P. Cocksedge, et al., The effect of dietary phytochemicals on nuclear factor erythroid 2-related factor 2 (Nrf2)activation: a systematic review of human intervention trials, Mol. Biol. Rep.48 (2021) 1745-1761. http://doi.org/10.1007/s11033-020-06041-x.
H. Lee, J. Lee, S.H. Hong, et al., Inhibition of RAGE attenuates cigarette smoke-induced lung epithelial cell damage via RAGE-mediated Nrf2/DAMP signaling, Front. Pharmacol. 9 (2018) 684. http://doi.org/10.3389/fphar.2018.00684.
A. Dominic, N.T. Le, M. Takahashi, Loop between NLRP3 inflammasome and reactive oxygen species, Antioxid. Redox Signal. 36 (2022) 784-796.https://doi.org/10.1089/ars.2020.8257.
D. Gao, J. Jiao, Z. Wang, et al., et al., The roles of cell-cell and organorgan crosstalk in the type 2 diabetes mellitus associated inflammatory microenvironment, Cytokine Growth Factor Rev. 66 (2022) 15-25. https://doi.org/10.1016/j.cytogfr.2022.04.002.
R. Zhou, A. Tardivel, B. Thorens, et al., Thioredoxin-interacting protein links oxidative stress to inflammasome activation, Nat. Immunol. 11 (2010)136-140. https://doi.org/10.1038/ni.1831.
P.Y. Tsai, S.M. Ka, J.M. Chang, et al., Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation, Free Radic. Biol. Med. 51 (2011) 744-754. https://doi.org/10.1016/j.freeradbiomed.2011.05.016.
M.E. Cavet, K.L. Harrington, T.R. Vollmer, et al., Anti-inflammatory and anti-oxidative effects of the green tea polyphenol epigallocatechin gallate in human corneal epithelial cells, Mol. Vis. 17 (2011) 533-542.
M. Molinari, K.D.S. Watt, T. Kruszyna, et al., Acute liver failure induced by green tea extracts: case report and review of the literature, Liver Transpl. 12(2006) 1892-1895. http://doi.org/10.1002/lt.21021.
Z. Bedrood, M. Rameshrad, H. Hosseinzadeh, Toxicological effects of Camellia sinensis (green tea): a review, Phytother. Res. 32 (2018) 1163-1180. http://doi.org/ 10.1002/ptr.6063.
J. Ouyang, K. Zhu, Z. Liu, et al., Prooxidant effects of epigallocatechin-3-gallate in health benefits and potential adverse effect, Oxid. Med. Cell Longev. 12 (2020) 9723686. http://doi.org/10.1155/2020/9723686.
M. Kanadzu, Y. Lu, K. Morimoto, Dual function of (−)-epigallocatechin gallate (EGCG) in healthy human lymphocytes, Cancer Lett. 241 (2005)250-255. http://doi.org/10.1016/j.canlet.2005.10.021.
755
Views
203
Downloads
0
Crossref
0
Web of Science
0
Scopus
0
CSCD
Altmetrics
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
